Akebia Therapeutics Inc (AKBA) Institutional Ownership & 13F Filings (Q2 2026)

AKBA ranks #3382 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AKBA is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

172 institutions disclose a position in AKBA, but none treat it as a major bet — even Virtus Advisers, LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Unified Investment Management has trimmed its AKBA position for two straight quarters, cutting it by $12.1K while still holding $12.9K.

AKBA is down 3.7% today, but institutions show net buying of $14.7M this quarter — a divergence between today's price move and the underlying institutional flow.

AKBA reported a net loss of $29.7M over the trailing twelve months.

• Not yet profitable — net loss of $29.7M over the trailing twelve months
• Revenue grew 7.5% year over year
• Net income improved year over year, from -$36.5M to -$29.7M
• Generated $68.0M in positive operating cash flow
• Current ratio of 1.55x — enough short-term assets to cover short-term liabilities
• Liabilities run 10.55x equity — a highly leveraged balance sheet worth noting